中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (6): 475-479.doi: 10.35541/cjd.20200912

• 论著 • 上一篇    下一篇

他扎罗汀倍他米松乳膏治疗斑块状银屑病后两种延长治疗方案的疗效和安全性的多中心临床观察

陈浩1    张理涛2    吕成志   杨秀敏4    胡凤鸣5    李雪飞6    张丽娟7    何春霞8    刁庆春9    夏秀娟10    路涛11    栗玉珍12    张汝芝13    孙建方1   

  1. 1中国医学科学院、北京协和医学院皮肤病医院病理科,南京  210042;2天津市中医药研究院附属医院皮肤科  300120;3大连市皮肤病医院皮肤科  116021;4首都医科大学附属北京同仁医院皮肤科  100730;5江西省皮肤病专科医院皮肤科,南昌  330200;6承德医学院附属医院皮肤科,河北  067000;7新疆医科大学第一附属医院皮肤科,乌鲁木齐 830054;8中国医学科学院、北京协和医学院北京协和医院皮肤科  100730;9重庆市中医院皮肤科  400013;10烟台毓璜顶医院皮肤科,山东  264000;11汕头大学医学院第一附属医院皮肤科,广东  515041;12哈尔滨医科大学附属第二医院皮肤科  150001;13常州市第一人民医院皮肤科,江苏  213003
  • 收稿日期:2020-09-14 修回日期:2021-03-29 发布日期:2021-05-31
  • 通讯作者: 孙建方 E-mail:fangmin5758@aliyun.com

Efficacy and safety of two prolonged therapeutic regimens in patients with plaque psoriasis after treatment with tazarotene/betamethasone dipropionate cream: a multicenter clinical observation

Chen Hao1, Zhang Litao2, Lyu Chengzhi3, Yang Xiumin4, Hu Fengming5, Li Xuefei6, Zhang Lijuan7, He Chunxia8, Diao Qingchun9, Xia Xiujuan10, Lu Tao11, Li Yuzhen12, Zhang Ruzhi13, Sun Jianfang1   

  1. 1Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China; 2Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin 300120, China; 3Department of Dermatology, Dalian Dermatosis Hospital, Dalian 116021, Liaoning, China; 4Department of Dermatology, Beijing Tongren Hospital of Capital Medical University, Beijing 100730, China; 5Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang 330200, China; 6Department of Dermatology, Affiliated Hospital of Chengde Medical College, Chengde 067000, Hebei, China; 7Department of Dermatology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China; 8Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; 9Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400013, China; 10Department of Dermatology, Yantai Yuhuangding Hospital, Yantai 264000, Shandong, China; 11Department of Dermatology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China; 12Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China; 13Department of Dermatology, The First People′s Hospital of Changzhou, Changzhou 213003, Jiangsu, China
  • Received:2020-09-14 Revised:2021-03-29 Published:2021-05-31
  • Contact: Sun Jianfang E-mail:fangmin5758@aliyun.com

摘要: 【摘要】 目的 探索使用他扎罗汀倍他米松乳膏治疗斑块状银屑病4周后有效但未达基愈患者的后续用药方案。方法 本研究采用多中心、随机、开放、平行、对照设计。232例完成0.05%/0.05%他扎罗汀倍他米松乳膏4周治疗,银屑病面积与严重性指数(PASI评分)改善在50% ~ 90%但未达基愈的斑块状银屑病受试者,在第5周时1∶1随机化进入试验组和对照组,试验组每日1次外用0.05%/0.05%他扎罗汀倍他米松乳膏,对照组每日1次序贯使用0.05%他扎罗汀凝胶、0.05%/0.05%他扎罗汀倍他米松乳膏(工作日使用他扎罗汀凝胶、周末使用他扎罗汀倍他米松乳膏),进行第5 ~ 8周的治疗,第6周和第8周时评价两组的疗效和安全性。两组间计量资料的比较采用协方差分析或t检验,计数资料的比较采用卡方检验。结果 232例进入第5 ~ 8周治疗的患者中,200例完成研究,试验组和对照组的全分析集(FAS)分别为110例、112例,安全性分析集(SAS)均为113例。连续治疗6周和8周后,试验组PASI评分的下降率分别为73.05% ± 16.69%和78.46% ± 15.40%,对照组分别下降66.73% ± 21.77%和67.02% ± 34.19%,两组比较,均P < 0.05。治疗6周后,试验组达到PASI90的受试者比例(14例,12.7%)高于对照组(5例,4.5%,χ2 = 4.842,P = 0.028);治疗8周后,试验组达到PASI75、PASI90的受试者比例(61.8%、23.6%)均高于对照组(48.2%、12.5%,均P < 0.05)。连续用药8周后,试验组和对照组的不良反应发生率(15.0%、23.9%)差异无统计学意义(χ2 = 2.822,P =0.093)。结论 使用0.05%/0.05%他扎罗汀倍他米松乳膏治疗银屑病4周后有效但未达基愈的患者,继续进行为期4周的0.05%/0.05%他扎罗汀倍他米松乳膏治疗是一种比序贯使用0.05%他扎罗汀凝胶、0.05%/0.05%他扎罗汀倍他米松乳膏更优的治疗方案。

关键词: 银屑病, 随机对照试验, 维生素A酸类, 他扎罗汀倍他米松乳膏

Abstract: 【Abstract】 Objective To explore the prolonged therapeutic regimen for patients with plaque psoriasis, who showed a positive response to 4-week treatment with tazarotene/betamethasone dipropionate cream, but were not completely cured. Methods A multicenter, randomized, open-labelled, parallel-controlled clinical study was conducted. A total of 232 patients with plaque psoriasis were collected, who showed a positive response to previous 4-week treatment with 0.05%/0.05% tazarotene/betamethasone dipropionate cream, but were not completely cured with the psoriasis area and severity index [PASI] improvement rate being 50% - 90%. At week 5, they were randomly and equally divided into 2 groups: test group receiving treatment with 0.05%/0.05% tazarotene/betamethasone dipropionate cream once a day, and control group receiving a sequential regimen of 0.05% tazarotene gel on weekdays once a day followed by 0.05%/0.05% tazarotene/betamethasone dipropionate cream on weekends once a day. After 2- and 4-week prolonged treatment, the efficacy and safety of the 2 therapeutic regimens were evaluated and compared. Measurement data were compared between 2 groups by using covariance analysis or t test, and enumeration data were compared by using chi-square test. Results From the 5th to the 8th week, 200 out of the 232 patients completed the treatment. Data collected from 110 patients in the test group and 112 in the control group were enrolled into the full analysis set, and those from both 113 patients in the test group and control group were enrolled into safety analysis set. After consecutive 6- and 8-week treatment, the decline rates of the PASI score were 73.05% ± 16.69% and 78.46% ± 15.40% respectively in the test group, which were significantly higher than those in the control group (66.73% ± 21.77%, 67.02% ± 34.19%, respectively, both P < 0.05). After 6-week treatment, the proportion of subjects who achieved PASI90 was significantly higher in the test group (14 cases, 12.7%) than in the control group (5 cases, 4.5%, χ2 = 4.842, P = 0.028); After 8-week treatment, the proportions of subjects who achieved PASI75 and PASI90 (61.8%, 23.6%, respectively) were significantly higher in the test group than in the control group (48.2%, 12.5%, respectively, both P < 0.05). During the consecutive 8-week treatment, there was no significant difference in the incidence rate of adverse reactions between the test group (15.0%) and control group (23.9%, χ2 = 2.822, P = 0.093). Conclusion For patients who showed a positive response to 4-week treatment with 0.05%/0.05% tazarotene/betamethasone dipropionate cream, but were not completely cured, the continuous use of 0.05%/0.05% tazarotene/betamethasone dipropionate cream for 4 weeks is a superior therapeutic regimen compared with the sequential regimen of 0.05% tazarotene gel followed by 0.05%/0.05% tazarotene/betamethasone dipropionate cream.

Key words: Psoriasis, Randomized controlled trial, Retinoids, Tazarotene/betamethasone dipropionate cream